CardiovascularMerck
Merck Reports Phase 3 Results for Tafolecimab in Hypercholesterolemia
BMI
Biotechnology Media Insights
Editorial Team · October 15, 2025
Merck announces Phase 3 trial results showing tafolecimab, a PCSK9 inhibitor, significantly reduces LDL cholesterol in patients with hypercholesterolemia.
Merck today announced Phase 3 trial results for tafolecimab, a fully human anti-PCSK9 monoclonal antibody, in patients with hypercholesterolemia. The trials demonstrated significant reductions in LDL cholesterol of approximately 60% compared to placebo when added to statin therapy.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.